Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of eye diseases and conditions. Shares of the eye care company are rallying 35% through early trading on Tuesday, August 23, 2022. Over the past three months, Aerie Pharmaceuticals has seen average daily volume of 646,200 shares. However, volume of 15.27 million shares or dollar volume of around $229.97 million, has already exchanged hands through early trading.

Shares of Aerie Pharmaceuticals are gaining after the company announced that it has entered into a definitive agreement to be acquired by Alcon (NYSE: ALC), an eye health care company with a 75-year history. Under the terms of the agreement, Alcon will acquire all outstanding shares of Aerie for $15.75 per share or a total transaction value of $770 million.

The acquisition comes as Alcon looks to bolster its commercial products and pipeline. Once the transaction is completed, Alcon will receive ownership of Aerie Pharmaceuticals’ Rocklatan and Rhopressa products, as well as several product candidates like AR-15512, a Phase 3 product to treat dry eye disease. The move comes as Alcon has been bolstering its ophthalmic pharmaceutical eye drop business through strategic product acquisitions of Simbrinza from Novartis in 2021 and Eysuvis and Inveltys from Kala Pharma in 2022.

The acquisition of Aerie Pharmaceuticals is estimated to close sometime during the fourth quarter of 2022, pending shareholder and regulatory approvals. Upon completion, Alcon is estimated to begin reflecting the transaction in its core EPS by 2024.

“Alcon is passionate about innovative treatments in eye care, especially in core disorders such as glaucoma and dry eye, which have significant patient impact,” said David Endicott, CEO of Alcon. “We have a 75-year history focused specifically on the eye and bring established expertise in development and commercial execution. Aerie is a natural fit with on-market and pipeline products, and R&D capabilities that offer the infrastructure needed to expand our ophthalmic pharmaceutical presence. As we continue to broaden our portfolio across glaucoma, retina and ocular surface disease, we are excited to help even more patients see brilliantly.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.